Purpose: The safety of nonsteroidal anti-inflammatory drugs (NSAIDs) commonly used in Asia-Pacific countries has had limited study. We assessed the risk of hospitalization for gastrointestinal events with loxoprofen and mefenamic acid compared with other NSAIDs in Asia-Pacific populations.
events with mefenamic acid was significantly lower in Taiwan (0.45; 95% CI, 0.26-0.78) and Korea (0.11; 95% CI, 0.05-0.27) but not Hong Kong (2.16; 95% CI, 0. 28-16.87 ), compared with diclofenac.
Conclusions: Compared with diclofenac, loxoprofen was associated with a lower risk of gastrointestinal hospitalizations in Korea and mefenamic acid with a lower risk in Taiwan and Korea.
KEYWORDS
anti-inflammatory agents, non-steroidal, pharmacoepidemiology
| INTRODUCTION
The Asian Pharmacoepidemiology Network (AsPEN) was formed to support the conduct of international pharmacoepidemiologic research and to facilitate prompt identification and validation of emerging safety concerns in Asian countries. 1, 2 Analyses have been conducted through this research network to build experience in using databases from AsPEN countries using a variety of methodological approaches, including sequence symmetry analysis. 3 AsPEN consists of research groups based in the Asia-Pacific region, including Australia, China, Hong Kong, Japan, Korea, Singapore, Taiwan, and Thailand.
It is well known that the use of nonselective nonsteroidal antiinflammatory drugs (NSAIDs) is associated with higher risks of upper and lower gastrointestinal events. 4, 5 Cyclooxygenase-2 (COX-2)
inhibitors, a selective NSAID, reduce the risk of gastrointestinal events because the inhibition of COX-2 does not affect the synthesis of prostaglandins that protect the gastrointestinal tract. 6, 7 However, the safety of NSAIDs that are commonly or solely used in the Asia-Pacific region, including loxoprofen and mefenamic acid, has not been well studied. Also, the majority of evidence comes from countries with predominantly Caucasian populations. It is unclear whether ethnic differences between Asian and Caucasian populations play a role in the comparative safety profiles of NSAIDs. [7] [8] [9] This international, multi-database cohort study aimed to compare the safety of loxoprofen and mefenamic acid with the safety other NSAIDs in terms of the risk of hospital admission for peptic ulcer diseases or upper and lower gastrointestinal bleeding. We compared patients who initiated loxoprofen or mefenamic acid with patients who initiated diclofenac, one of the commonly used and previously studied NSAIDs. We also included celecoxib in the study to benchmark the effect for COX-2 inhibitors with nonselective NSAIDs.
2 | METHOD
| Distributed network approach with a common data model
We conducted a retrospective, multi-database, international pharmacoepidemiologic study using a distributed network approach [10] [11] [12] and developed a study-specific common data model consisting of eight tables, including patient demographic characteristics, eligibility, drug, inpatient encounter, inpatient diagnosis, outpatient diagnosis, inpatient procedures, and outpatient procedures (eMethods). Teams from all participating countries converted their original data structures to the common data model before analyses. The coordinating center generated a systematic SAS program based on the study protocol and distributed it to each site. The results of the analyses were then returned to the coordinating center for collating.
| Participating databases
Participating countries included Australia, Hong Kong, Japan, Korea, and Taiwan. We included data from the Japan Medical Data Centre elsewhere. 2 The study has been approved by the IRB from each site.
| Study cohort definitions
We selected patients who initiated NSAIDs (ie, diclofenac, loxoprofen, mefenamic acid, and celecoxib). We considered the first dispensed NSAID to be the index medication, and we used the dispensing date as the index date. We included only new users of NSAIDs, which we defined as patients who received no dispensing of an NSAID during
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the 6 months before the index date. Although use of nonprescription NSAIDs is not common in Asian countries, 13 was switched from the index medication, discontinued the medication (ie, had no dispensing for more than 14 days after the end date of the previous dispensing), discontinued enrollment in the databases, reached the end of the study follow-up, or died. We also calculated the number of gastrointestinal adverse event cases by specific gastrointestinal event, drug type, and site.
| Covariate and statistical analyses
We report means and SDs for continuous variables and frequencies for dichotomous variables. We report the number of events and the incidence per person-year for the outcomes of interest. We estimated hazard ratios (HRs) and 95% CIs using Cox proportional hazards models to assess the risks of hospital admission for gastrointestinal events associated with initiation of loxoprofen, mefenamic acid, or celecoxib compared with diclofenac. We adjusted for demographic characteristics to account for potential confounding. Using inpatient and outpatient prescription data, diagnoses, and procedure data from the 180 days before the index date, we identified up to 500 covariates by high-dimensional propensity score (hdPS) 17 and matched on hdPS using 5-to-1 greedy matching to control for confounders and unobserved factors.
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We selected hdPS for confounding adjustment for two reasons: First, the hdPS approach is likely to result in less residual confounding than conventional approaches, such as multivariable regression or a propensity score method using prespecified covariates, because hdPS allows data-driven selection of confounders that can be unique to each country. Second, the hdPS approach allows us to maintain data confidentiality when pooling results without sharing identifiable data.
To evaluate the impact of censoring, we conducted an intentionto-treat analysis in which we considered patients to be exposed to the index medication until the occurrence of events, death, or the end of follow-up, regardless of subsequent changes in exposure. We limited the follow-up period to 1 year for the intention-to-treat analysis. We used SAS version 9.3 (SAS Institute, Inc) for all analyses.
This project was approved by the institutional review board of the Duke University Health System.
| RESULTS
We Table 3 . We present the number of gastrointestinal adverse event cases by specific end point, drug type, and site in eTable 2. Specifically, we found most of the events were peptic ulcer disease and unspecified site of gastrointestinal bleeding.
| DISCUSSION
We used five nationwide databases from Australia, Hong Kong, Japan, Korea, and Taiwan to assess the comparative gastrointestinal safety of NSAIDs that are commonly or solely used in the Asia-Pacific region.
We found loxoprofen and mefenamic acid had lower risks of gastrointestinal events requiring hospitalization compared with diclofenac in Korea. To benchmark the effect size the risk of gastrointestinal events, we selected celecoxib as the reference indicator for COX-2 inhibitors known to have a better gastrointestinal safety profile. 22 We found that loxoprofen and mefenamic acid may have similar or better gastrointestinal safety profiles than celecoxib.
Loxoprofen is a commonly used NSAID in Japan and Korea but is not marketed in other parts of the world except in Brazil. 23, 24 Loxoprofen is a pro-drug, which attenuates the inhibition of prostaglandin synthesis in the local gastrointestinal tract and mucosa and avoids topical irritation due to the presence of the free carboxylic group of the NSAIDs and low direct cytotoxicity on mucosal cells. [25] [26] [27] However, a case-control study in Japan found a similar risk of upper gastrointestinal bleeding with loxoprofen as with aspirin and diclofenac. 23 Our study supports this finding, as we observed that loxoprofen appeared to be associated with a higher risk of gastrointestinal events requiring hospitalization than diclofenac in Japan, although the association remained inconclusive because of the small sample size and low statistical power. By comparison, we observed a favorable gastrointestinal risk with loxoprofen in the Korean population. One possible explanation for this difference is that the Korean patients were older, and the benefit of the pro-drug characteristics of loxoprofen was greater in older patients who may be vulnerable to gastrointestinal events. Another possible explanation is that the injection form of diclofenac, which may increase gastrointestinal events and decrease the relative hazard of loxoprofen, has been more frequently prescribed in Korea than in other countries. a nationwide case-crossover study using a Taiwanese database and found that mefenamic acid had a lower risk of hospitalization for gastrointestinal events than other NSAIDs, including diclofenac. Our findings support the results of previous studies, although the risk estimates from Hong Kong's database were unstable because of the small sample size. However, the potential associations of mefenamic acid with risks of nephrotoxicity and neurotoxicity in elderly patients may also be a concern. 30 Celecoxib, a selective COX-2 inhibitor, has been associated with a significantly lower frequency of gastrointestinal adverse events than nonselective NSAIDs. 22, 31 Our findings in Korea and Australia are consistent with previous observational studies that celecoxib has lower risk than diclofenac. However, we did not find a significant benefit in terms of gastrointestinal safety in Taiwan. This finding may be a result of uncontrolled selection bias, because use of celecoxib in Taiwan is only covered for patients with certain conditions, including previous history of gastrointestinal ulcer or bleeding, leading to a higher baseline risk of gastrointestinal events in celecoxib initiators.
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The distributed network approach using a common data model and executing a systematic program based on a common data structure provided the advantage of controlling the quality of the analyses. This approach has been widely used in other academic networks. 1, 3, 11 However, concerns about data privacy impede the pooling of individual patient data. Our study highlights the importance of evaluating older medicines that are used commonly in Asian countries. The use of more expensive COX-2 inhibitors may increase the economic burden in the health care system, especially for countries with moderate income. 32 If less costly loxoprofen and mefenamic acid pose favorable gastrointestinal safety profiles, they could play a role in curbing the high cost of pain control. 6, 32 This is the first multi-database, international pharmacoepidemiologic study in an Asia-Pacific population, and implementation of the study holds a number of lessons for future international pharmacoepidemiologic studies in Asia. There were several challenges in the implementation of the study. First, differences among countries in health care systems and medical practice led to potential biases. For example, we observed a wide range of incidence rates for gastrointestinal bleeding events. It has been reported previously that the hospital admission rate for upper gastrointestinal complications in Taiwan may be high due to either the convenience of the health care system or relatively low medical costs. 33 This is reflected in our finding that the overall incidence of hospital admission for gastrointestinal events was higher in Taiwan than in other countries except Hong Kong. The high rate in Hong Kong may be a result of the nature of the hospital-based electronic health records and the insurance system.
That is, the selected patients were generally experiencing more severe conditions, giving rise to higher likelihood of adverse events occurrence. In addition, sicker patients may have had more complete information in the hospital-based electronic health records and therefore greater likelihood of being detected. 34 However, the number of selected patients in Hong Kong in the study was low, leading to unstable estimates. On the other hand, it has been reported that the persistence of the use of NSAIDs was low, leading to the possibility to underestimation of gastrointestinal events in Korea because of temporal use of NSAIDs and lost follow-up. Second, the validity of the selected ICD-9 and ICD-10 codes in the different databases was uncertain, which might also cause possible misclassification bias of the analyses. Therefore, the study focused on events requiring hospitalization to increase the internal validity of the analyses and to minimize bias. It is noteworthy that the comparisons of characteristics among countries should be careful because the differences could result from underlying causes. Possible reasons, for example, could be include differences in the nature of the databases, medical systems, and the thresholds of diagnosis or use of medications. Despite the variability in characteristics of patients and incidence rates of gastrointestinal events, it should not affect the validity of relative hazards comparing different NSAIDs within countries, because the definitions we used are likely to be highly specific based on existing studies. 14, 15 Third, as in previous studies in the AsPEN network, there was variability in the products available across countries and the preference and indication of medicines within countries. This is a particular challenge in comparative effective and safety studies across countries with different regulatory conditions. Many other networks such as the
Exploring and Understanding Adverse Drug Reactions project in
Europe and the Mini-Sentinel project in the United States combine databases under similar regulatory frameworks, which mean that in general the indications and the availability of the medicines are more consistent across databases than across Asian countries. We were unable to describe the distribution of covariates. To enhance control for confounding, we allowed data-driven selection of confounders unique to each country using hdPS and did not perform multivariate analyses using predefined covariates. Fourth, we censored data for patients at the time of switching to a different NSAID. However, because the reasons for switching were not available in the databases, it impossible to assess whether the switching is associated with the study end point and the possibility of informative censoring cannot be excluded, which will likely bring the results toward null for NSAIDs that may cause higher rates of gastrointestinal symptoms. From the post hoc analysis, we found a significant number of gastrointestinal bleeding events were coded as unspecified sites representing the clinical nature of bleeding; the site of bleeding may not be identified clinically in many cases. Also, the validity of each gastrointestinal end point has not been examined in Asian databases. Future studies may consider collecting information from hospital medical records to validate these specific gastrointestinal events and confirm the risks on these specific gastrointestinal end point.
In conclusion, this study largely supports previous evidence from countries outside of the Asia-Pacific region that patients initiating treatment with loxoprofen and mefenamic acid had lower risk of gastrointestinal events compared with patients initiating diclofenac in most but not all countries. In addition, our study provides lessons for future international pharmacoepidemiologic studies in the AsiaPacific region.
